Colchicine salicylate | 8013-62-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Colchicine salicylate
• 英文别名: 2-hydroxybenzoic acid;N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
• CAS: 8013-62-5
• 化学式: C29H31NO9
• 分子量: 537.6
• InChiKey: FJDBYGKCGURUGE-NTISSMGPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.96
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  141
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• COLCHICINE SALICYLATE AND USES THEREOF
  申请人：Murray And Poole Enterprises Limited

  公开号：EP3283063A1

  公开（公告）日：2018-02-21
• COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS B VIRUS INFECTION
  申请人：Anhui Ronghang Biotech Development Co., Ltd.

  公开号：EP3989956A1

  公开（公告）日：2022-05-04
• COLCHICINE SALICYLATE DERIVATIVES AND METHODS OF TREATMENT
  申请人：Murray and Poole Enterprises Limited

  公开号：US20180318221A1

  公开（公告）日：2018-11-08

  Pharmaceutical compositions of colchicine salicylate, including once-a-day orally administered formulations are provided. Method of treating and/or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
• [EN] COLCHICINE SALICYLATE AND USES THEREOF<br/>[FR] SALICYLATE DE COLCHICINE ET SES UTILISATIONS
  申请人：MURRAY AND POOLE ENTPR LTD

  公开号：WO2016166732A1

  公开（公告）日：2016-10-20

  Pharmaceutical compositions of colchicine salicylate, including once-a-day orally administered formulations are provided. Method of treating and/or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.
• [EN] COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS B VIRUS INFECTION<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：ANHUI RONGHANG BIOTECH DEV CO LTD

  公开号：WO2020258211A1

  公开（公告）日：2020-12-30

  A pharmaceutical composition and kits thereof for treatment of HBV infection comprises colchicine and CYP3A4 /P-gp inhibitor.